A Nanoparticle Carrying the p53 Gene Targets Tumors Including Cancer Stem Cells, Sensitizes Glioblastoma to Chemotherapy and Improves Survival

Temozolomide (TMZ)-resistance in glioblastoma multiforme (GBM) has been linked to upregulation of O6-methylguanine-DNA methyltransferase (MGMT). Wild-type (wt) p53 was previously shown to down-modulate MGMT. However, p53 therapy for GBM is limited by lack of efficient delivery across the blood brain barrier (BBB). We have developed a systemic nanodelivery platform (scL) for tumor-specific targeting (primary and metastatic), which is currently in multiple clinical trials. This self-assembling nanocomplex is formed by simple mixing of the components in a defined order and a specific ratio. Here, we demonstrate that scL crosses the BBB and efficiently targets GBM, as well as cancer stem cells (CSCs), which have been implicated in recurrence and treatment resistance in many human cancers. Moreover, systemic delivery of scL-p53 down-modulates MGMT and induces apoptosis in intracranial GBM xenografts. The combination of scL-p53 and TMZ increased the antitumor efficacy of TMZ with enhanced survival benefit in a mouse model of highly TMZ-resistant GBM. scL-p53 also sensitized both CSCs and bulk tumor cells to TMZ, increasing apoptosis. These results suggest that combining scL-p53 with standard TMZ treatment could be a more effective therapy for GBM.

[1]  Gerald C. Chu,et al.  Pten and p53 converge on c-Myc to control differentiation, self-renewal, and transformation of normal and neoplastic stem cells in glioblastoma. , 2008, Cold Spring Harbor symposia on quantitative biology.

[2]  J. Sarkaria,et al.  Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model , 2009, Journal of Neuro-Oncology.

[3]  I. Germano,et al.  Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. , 2003, Journal of neurosurgery.

[4]  Gerald C. Chu,et al.  P53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation , 2008, Nature.

[5]  E. Chang,et al.  Transferrin-liposome-mediated systemic p53 gene therapy in combination with radiation results in regression of human head and neck cancer xenografts. , 1999, Human gene therapy.

[6]  M. Weller,et al.  O6‐methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells , 2006, Journal of neurochemistry.

[7]  L. Tentori,et al.  Recent approaches to improve the antitumor efficacy of temozolomide. , 2009, Current medicinal chemistry.

[8]  C. Beier,et al.  Chemoresistance of glioblastoma cancer stem cells - much more complex than expected , 2011, Molecular Cancer.

[9]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[10]  R. McLendon,et al.  Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  E. Chang,et al.  Systemic tumor-targeted gene delivery by anti-transferrin receptor scFv-immunoliposomes. , 2002, Molecular cancer therapeutics.

[12]  Sophie Martin,et al.  Integrins and p53 pathways in glioblastoma resistance to temozolomide , 2012, Frontiers in Oncology.

[13]  N. Socci,et al.  Phase II trial of neoadjuvant temozolomide in resectable melanoma patients. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Qi Zhou,et al.  Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. , 2007, Cancer research.

[15]  R. Müller,et al.  Transfection with different colloidal systems: comparison of solid lipid nanoparticles and liposomes. , 2004, Journal of controlled release : official journal of the Controlled Release Society.

[16]  W. Yung,et al.  Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis. , 2001, Neuro-oncology.

[17]  M. Chamberlain.  Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas , 2010, Expert review of neurotherapeutics.

[18]  J. Dagata,et al.  Physical characterization methods for iron oxide contrast agents encapsulated within a targeted liposome-based delivery system , 2008, Nanotechnology.

[19]  Shiladitya Sengupta,et al.  p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. , 2009, Anticancer research.

[20]  Qi Zhou,et al.  Tumor-targeting nanodelivery enhances the anticancer activity of a novel quinazolinone analogue , 2008, Molecular Cancer Therapeutics.

[21]  Shutao Guo,et al.  Nanoparticles escaping RES and endosome: challenges for siRNA delivery for cancer therapy , 2011 .

[22]  Darell D. Bigner,et al.  Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.

[23]  Y. Kawashima,et al.  A novel method for measuring rigidity of submicron-size liposomes with atomic force microscopy. , 2008, International journal of pharmaceutics.

[24]  G. Kloecker,et al.  A Phase I study of thalidomide, Capecitabine and temozolomide in advanced cancer , 2007, Cancer biology & therapy.

[25]  Jeffrey W. Clark,et al.  O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .

[26]  M. Mohiuddin,et al.  Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. , 1997, Cancer research.

[27]  Yonghuan Jin,et al.  Activation of AMP-activated Protein Kinase by Temozolomide Contributes to Apoptosis in Glioblastoma Cells via p53 Activation and mTORC1 Inhibition* , 2010, The Journal of Biological Chemistry.

[28]  J. Cairncross,et al.  Pharmaceutical‐mediated inactivation of p53 sensitizes U87MG glioma cells to BCNU and temozolomide , 2005, International journal of cancer.

[29]  J. Cairncross,et al.  Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma , 2011, Journal of Neuro-Oncology.

[30]  Louis M Weiner,et al.  The clinical potential of targeted nanomedicine: delivering to cancer stem-like cells. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[31]  G. Barger,et al.  In vitro Drug Response and Molecular Markers Associated with Drug Resistance in Malignant Gliomas , 2006, Clinical Cancer Research.

[32]  C. James,et al.  Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts. , 2009, International journal of radiation oncology, biology, physics.

[33]  M. Berger,et al.  p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. , 2001, Cancer research.

[34]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[35]  Natalia Farkas,et al.  Combined scanning probe and light scattering characterization of multi-stage self-assembly of targeted liposome-based delivery systems , 2011 .

[36]  L. Ricci-Vitiani,et al.  Chemotherapy resistance of glioblastoma stem cells , 2006, Cell Death and Differentiation.

[37]  Qi Zhou,et al.  Tumor-targeting nanoimmunoliposome complex for short interfering RNA delivery. , 2005, Human gene therapy.

[38]  M. Weller,et al.  Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine , 2007, Oncogene.

[39]  A. Braun,et al.  Revisiting the role of p53 in primary and secondary glioblastomas. , 2006, Anticancer research.

[40]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[41]  V. Tse,et al.  Recurrent glioblastoma multiforme: a review of natural history and management options. , 2006, Neurosurgical focus.

[42]  Qi Zhou,et al.  Tumor-Targeting Nanocomplex Delivery of Novel Tumor Suppressor RB94 Chemosensitizes Bladder Carcinoma Cells In vitro and In vivo , 2008, Clinical Cancer Research.

[43]  D. Schadendorf,et al.  Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032). , 2011, European journal of cancer.

[44]  P. Mischel,et al.  Charting the course across the blood-brain barrier. , 2011, The Journal of clinical investigation.

[45]  E. Chang,et al.  Self-assembly of a virus-mimicking nanostructure system for efficient tumor-targeted gene delivery. , 2002, Human gene therapy.

[46]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[47]  P. Dubois,et al.  Influence of DNA condensation state on transfection efficiency in DNA/polymer complexes: an AFM and DLS comparative study. , 2006, Journal of biotechnology.

[48]  M. Weller,et al.  Modulation of MDR/MRP by wild-type and mutant p53. , 2001, The Journal of clinical investigation.

[49]  C. Goh,et al.  Combined radiation and p53 gene therapy of malignant glioma cells , 1999, Cancer Gene Therapy.

[50]  K. Srivenugopal,et al.  Enforced expression of wild-type p53 curtails the transcription of the O(6)-methylguanine-DNA methyltransferase gene in human tumor cells and enhances their sensitivity to alkylating agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  T. Wakabayashi,et al.  Current Trends in Targeted Therapies for Glioblastoma Multiforme , 2012, Neurology research international.

[52]  Karin Reed,et al.  Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. , 2002, Biochemical pharmacology.

[53]  M. Davies,et al.  Atomic Force Microscopy of Cationic Liposomes , 2000 .

[54]  G. Fròsina.  DNA Repair and Resistance of Gliomas to Chemotherapy and Radiotherapy , 2009, Molecular Cancer Research.

[55]  U. Schubert,et al.  Aqueous micelles from supramolecular graft copolymers , 2003 .

[56]  J. Cairncross,et al.  Inactivation of p53 Sensitizes Astrocytic Glioma Cells to BCNU and Temozolomide, but not Cisplatin , 2005, Journal of Neuro-Oncology.

[57]  Antonina Rait,et al.  Phase I study of a systemically delivered p53 nanoparticle in advanced solid tumors. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  L. Crinò,et al.  Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[59]  Lili Liu,et al.  Targeted Modulation of MGMT: Clinical Implications , 2006, Clinical Cancer Research.

[60]  S. Konduri,et al.  Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide. , 2010, Neuro-oncology.

[61]  Ezequiel Bernabeu,et al.  The transferrin receptor and the targeted delivery of therapeutic agents against cancer. , 2012, Biochimica et biophysica acta.

[62]  D. Bar-Sagi,et al.  Signaling endosomes: seeing is believing. , 2010, Current opinion in cell biology.

[63]  C. Marosi.  Complications of chemotherapy in neuro-oncology. , 2012, Handbook of clinical neurology.

[64]  A. Ruiz i Altaba,et al.  NANOG regulates glioma stem cells and is essential in vivo acting in a cross‐functional network with GLI1 and p53 , 2010, The EMBO journal.

[65]  R. Bjerkvig,et al.  DNA repair and cancer stem-like cells--potential partners in glioma drug resistance? , 2008, Cancer treatment reviews.

[66]  Jeffrey W. Clark,et al.  Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  B. Teicher,et al.  Antiangiogenic and antitumor effects of a protein kinase Cbeta inhibitor in human T98G glioblastoma multiforme xenografts. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[68]  Soojin Park,et al.  Physicochemical characterization of self-assembled poly(∈-caprolactone) grafted dextran nanoparticles , 2008 .

[69]  D. Benharroch,et al.  Acquired resistance to 6-thioguanine in melanoma cells involves the repair enzyme O6- methylguanine-DNA methyltransferase (MGMT). , 2010, Cancer biology & therapy.

[70]  Qi Zhou,et al.  Enhanced transfection efficiency of a systemically delivered tumor-targeting immunolipoplex by inclusion of a pH-sensitive histidylated oligolysine peptide. , 2004, Nucleic acids research.

[71]  Junnian Zheng,et al.  A novel approach to overcome temozolomide resistance in glioma and melanoma: Inactivation of MGMT by gene therapy. , 2011, Biochemical and biophysical research communications.

[72]  I. Yang,et al.  Temozolomide and other potential agents for the treatment of glioblastoma multiforme. , 2012, Neurosurgery clinics of North America.

[73]  Andreas von Deimling,et al.  Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? , 2011, Radiation oncology.

[74]  E. Chang,et al.  Systemic p53 Gene Therapy of Cancer with Immunolipoplexes Targeted by Anti-Transferrin Receptor scFv , 2001, Molecular medicine.